Deconstructing schizophrenia: advances in preclinical models for biomarker identification

Judith A Pratt, Brian Morris, Neil Dawson

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Schizophrenia is considered to develop as a consequence of genetic and environmental factors impacting on brain neural systems and circuits during vulnerable neurodevelopmental periods, thereby resulting in symptoms in early adulthood. Understanding of the impact of schizophrenia risk factors on brain biology and behaviour can help in identifying biologically relevant pathways that are attractive for informing clinical studies and biomarker development. In this chapter, we emphasize the importance of adopting a reciprocal forward and reverse translation approach that is iteratively updated when additional new information is gained, either preclinically or clinically, for offering the greatest opportunity for discovering panels of biomarkers for the diagnosis, prognosis and treatment of schizophrenia. Importantly, biomarkers for identifying those at risk may inform early intervention strategies prior to the development of schizophrenia. Given the emerging nature of this approach in the field, this review will highlight recent research of preclinical biomarkers in schizophrenia that show the most promise for informing clinical needs with an emphasis on relevant imaging, electrophysiological, cognitive behavioural and biochemical modalities. The implementation of this reciprocal translational approach is exemplified firstly by the production and characterization of preclinical models based on the glutamate hypofunction hypothesis, genetic and environmental risk factors for schizophrenia (reverse translation), and then the recent clinical recognition of the thalamic reticular thalamus (TRN) as an important locus of brain dysfunction in schizophrenia as informed by preclinical findings (forward translation).

LanguageEnglish
Title of host publicationCurrent Topics in Behavioral Neurosciences
Place of PublicationBerlin
PublisherSpringer
Number of pages29
DOIs
Publication statusE-pub ahead of print - 3 May 2018

Publication series

NameCurrent Topics in Behavioral Neurosciences
PublisherSpringer
ISSN (Print)1866-3370

Fingerprint

Schizophrenia
Biomarkers
Brain
Thalamus
Glutamic Acid
Research

Keywords

  • schizophrenia
  • biomarkers
  • neuroscience

Cite this

Pratt, J. A., Morris, B., & Dawson, N. (2018). Deconstructing schizophrenia: advances in preclinical models for biomarker identification. In Current Topics in Behavioral Neurosciences (Current Topics in Behavioral Neurosciences). Berlin: Springer. https://doi.org/10.1007/7854_2018_48
Pratt, Judith A ; Morris, Brian ; Dawson, Neil. / Deconstructing schizophrenia : advances in preclinical models for biomarker identification. Current Topics in Behavioral Neurosciences. Berlin : Springer, 2018. (Current Topics in Behavioral Neurosciences).
@inbook{309f84e72939428f8fe2336c51d692c9,
title = "Deconstructing schizophrenia: advances in preclinical models for biomarker identification",
abstract = "Schizophrenia is considered to develop as a consequence of genetic and environmental factors impacting on brain neural systems and circuits during vulnerable neurodevelopmental periods, thereby resulting in symptoms in early adulthood. Understanding of the impact of schizophrenia risk factors on brain biology and behaviour can help in identifying biologically relevant pathways that are attractive for informing clinical studies and biomarker development. In this chapter, we emphasize the importance of adopting a reciprocal forward and reverse translation approach that is iteratively updated when additional new information is gained, either preclinically or clinically, for offering the greatest opportunity for discovering panels of biomarkers for the diagnosis, prognosis and treatment of schizophrenia. Importantly, biomarkers for identifying those at risk may inform early intervention strategies prior to the development of schizophrenia. Given the emerging nature of this approach in the field, this review will highlight recent research of preclinical biomarkers in schizophrenia that show the most promise for informing clinical needs with an emphasis on relevant imaging, electrophysiological, cognitive behavioural and biochemical modalities. The implementation of this reciprocal translational approach is exemplified firstly by the production and characterization of preclinical models based on the glutamate hypofunction hypothesis, genetic and environmental risk factors for schizophrenia (reverse translation), and then the recent clinical recognition of the thalamic reticular thalamus (TRN) as an important locus of brain dysfunction in schizophrenia as informed by preclinical findings (forward translation).",
keywords = "schizophrenia , biomarkers , neuroscience",
author = "Pratt, {Judith A} and Brian Morris and Neil Dawson",
year = "2018",
month = "5",
day = "3",
doi = "10.1007/7854_2018_48",
language = "English",
series = "Current Topics in Behavioral Neurosciences",
publisher = "Springer",
booktitle = "Current Topics in Behavioral Neurosciences",

}

Pratt, JA, Morris, B & Dawson, N 2018, Deconstructing schizophrenia: advances in preclinical models for biomarker identification. in Current Topics in Behavioral Neurosciences. Current Topics in Behavioral Neurosciences, Springer, Berlin. https://doi.org/10.1007/7854_2018_48

Deconstructing schizophrenia : advances in preclinical models for biomarker identification. / Pratt, Judith A; Morris, Brian; Dawson, Neil.

Current Topics in Behavioral Neurosciences. Berlin : Springer, 2018. (Current Topics in Behavioral Neurosciences).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Deconstructing schizophrenia

T2 - advances in preclinical models for biomarker identification

AU - Pratt, Judith A

AU - Morris, Brian

AU - Dawson, Neil

PY - 2018/5/3

Y1 - 2018/5/3

N2 - Schizophrenia is considered to develop as a consequence of genetic and environmental factors impacting on brain neural systems and circuits during vulnerable neurodevelopmental periods, thereby resulting in symptoms in early adulthood. Understanding of the impact of schizophrenia risk factors on brain biology and behaviour can help in identifying biologically relevant pathways that are attractive for informing clinical studies and biomarker development. In this chapter, we emphasize the importance of adopting a reciprocal forward and reverse translation approach that is iteratively updated when additional new information is gained, either preclinically or clinically, for offering the greatest opportunity for discovering panels of biomarkers for the diagnosis, prognosis and treatment of schizophrenia. Importantly, biomarkers for identifying those at risk may inform early intervention strategies prior to the development of schizophrenia. Given the emerging nature of this approach in the field, this review will highlight recent research of preclinical biomarkers in schizophrenia that show the most promise for informing clinical needs with an emphasis on relevant imaging, electrophysiological, cognitive behavioural and biochemical modalities. The implementation of this reciprocal translational approach is exemplified firstly by the production and characterization of preclinical models based on the glutamate hypofunction hypothesis, genetic and environmental risk factors for schizophrenia (reverse translation), and then the recent clinical recognition of the thalamic reticular thalamus (TRN) as an important locus of brain dysfunction in schizophrenia as informed by preclinical findings (forward translation).

AB - Schizophrenia is considered to develop as a consequence of genetic and environmental factors impacting on brain neural systems and circuits during vulnerable neurodevelopmental periods, thereby resulting in symptoms in early adulthood. Understanding of the impact of schizophrenia risk factors on brain biology and behaviour can help in identifying biologically relevant pathways that are attractive for informing clinical studies and biomarker development. In this chapter, we emphasize the importance of adopting a reciprocal forward and reverse translation approach that is iteratively updated when additional new information is gained, either preclinically or clinically, for offering the greatest opportunity for discovering panels of biomarkers for the diagnosis, prognosis and treatment of schizophrenia. Importantly, biomarkers for identifying those at risk may inform early intervention strategies prior to the development of schizophrenia. Given the emerging nature of this approach in the field, this review will highlight recent research of preclinical biomarkers in schizophrenia that show the most promise for informing clinical needs with an emphasis on relevant imaging, electrophysiological, cognitive behavioural and biochemical modalities. The implementation of this reciprocal translational approach is exemplified firstly by the production and characterization of preclinical models based on the glutamate hypofunction hypothesis, genetic and environmental risk factors for schizophrenia (reverse translation), and then the recent clinical recognition of the thalamic reticular thalamus (TRN) as an important locus of brain dysfunction in schizophrenia as informed by preclinical findings (forward translation).

KW - schizophrenia

KW - biomarkers

KW - neuroscience

U2 - 10.1007/7854_2018_48

DO - 10.1007/7854_2018_48

M3 - Chapter

T3 - Current Topics in Behavioral Neurosciences

BT - Current Topics in Behavioral Neurosciences

PB - Springer

CY - Berlin

ER -

Pratt JA, Morris B, Dawson N. Deconstructing schizophrenia: advances in preclinical models for biomarker identification. In Current Topics in Behavioral Neurosciences. Berlin: Springer. 2018. (Current Topics in Behavioral Neurosciences). https://doi.org/10.1007/7854_2018_48